Key Highlights
- Income per share was USD 0.04 against an estimate of a USD 3.55 loss.
- Total Revenue was USD 1.76 million, compared with USD 1.08 million.
- Net income was USD 157 thousand, compared with USD 200.64 million.
- Gain on Debt restructuring was USD 14.01 million in the quarter.
Kyntra Bio (NASDAQ:KYNB) reported total revenue of USD 1.76 million for the third quarter of 2026, compared with USD 1.08 million in the prior-year quarter. Basic and diluted income per share from continuing operations was USD 0.04, compared with a loss of USD 3.25, against an estimate of a USD 3.55 loss.
Net income was USD 157 thousand, compared with USD 200.64 million, which included income from discontinued operations of USD 213.78 million in the prior-year quarter. The company describes itself as a pure play, rare disease biopharmaceutical company focused on the development of roxadustat for anemia associated with lower-risk myelodysplastic syndromes.
Third Quarter Results
Development and other revenue was USD 99 thousand, compared with USD 119 thousand, and drug product revenue, net, was USD 1.66 million, compared with USD 957 thousand. Cost of Goods Sold was USD 619 thousand, compared with a Credit of USD 58 thousand. Research and Development expenses were USD 8.27 million, compared with USD 1.21 million, and selling, general and administrative expenses were USD 5.76 million, compared with USD 5.30 million.
Total operating costs and expenses were USD 14.63 million, compared with USD 6.49 million, and the loss from operations was USD 12.87 million, compared with USD 5.41 million. Interest expense was USD 1.63 million, compared with USD 2.08 million, and the company recorded a gain on debt restructuring of USD 14.01 million. Total interest and other, net, was USD 13.02 million, compared with expense of USD 7.74 million.
Nine-Month Results
For the nine months ended September 30, 2026, total revenue was USD 4.03 million, compared with USD 5.16 million. Research and development expenses were USD 22.65 million, compared with USD 16.25 million, and the loss from operations was USD 44.26 million, compared with USD 32.38 million. The company recorded a gain on deconsolidation of a Subsidiary of USD 30.94 million.
The loss from continuing operations was USD 3.00 million, compared with USD 43.59 million, and the net loss was USD 3.07 million, compared with Net Income of USD 197.67 million. Loss per share from continuing operations was USD 0.74, compared with USD 10.79.
Balance Sheet and Liquidity
Cash and cash equivalents were USD 9.91 million at September 30, 2026, compared with USD 47.87 million at December 31, 2025, and short-term investments were USD 30.39 million, compared with USD 41.11 million. Accounts receivable, net, were USD 3.85 million, and inventories were USD 3.26 million.
Total Assets were USD 48.85 million, compared with USD 119.59 million, and total current liabilities were USD 41.76 million, compared with USD 29.24 million. Total liabilities were USD 56.04 million, compared with USD 115.12 million. The company stated that, based on its current operating plans, it anticipates that its cash, cash equivalents, investments and Accounts Receivable are sufficient to fund operations into 2028, while noting it may exhaust its Capital resources sooner and may need additional funding earlier than planned. The company had 4,049,985 shares of common stock outstanding as of October 31, 2026.
Kyntra Bio Q3 2026 Earnings: Key Takeaways
Kyntra Bio reported third quarter 2026 total revenue of USD 1.76 million and net income of USD 157 thousand, including a gain on debt restructuring of USD 14.01 million. Cash and short-term investments totaled USD 9.91 million and USD 30.39 million at September 30, 2026.






Please wait processing your request...